Physician profile
Jonathan Lavian
NPI 1801327309
$4,726.02
in general payments reported to CMS, 2019-2025
24 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $133 · 2021: $295 · 2022: $593 · 2023: $524 · 2024: $1,027 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,358 · Education: $87.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,357.60 |
| Education | $87.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,024.08 | 2019-2025 | Dupixent, Libtayo |
| Abbvie INC. | $632.79 | 2019-2025 | |
| Genzyme Corporation | $386.74 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $308.66 | 2022-2025 | Blu-U |
| Ucb, INC. | $294.08 | 2023-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $258.55 | 2023-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $251.94 | 2023-2024 | Vtama |
| Incyte Corporation | $242.95 | 2024-2025 | Opzelura |
| Janssen Biotech, INC. | $234.56 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $189.39 | 2022-2025 | |
| Amgen INC. | $165.03 | 2023-2025 | Otezla, Otezla |
| Leo Pharma INC. | $139.04 | 2023-2025 | Adbry |
| Lilly USA, LLC | $103.57 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $103.50 | 2022-2025 | Sotyktu |
| Allergan, INC. | $97.33 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $65.44 | 2025 | Vtama |
| Pfizer INC. | $65.19 | 2022-2024 | |
| Almirall LLC | $42.14 | 2025 | Klisyri, Seysara |
| Fresenius Kabi USA, LLC | $32.19 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.43 | 2022 | |
| Phadia US INC. | $18.19 | 2023 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $16.83 | 2024 | Simlandi |
| Arcutis Biotherapeutics, INC. | $16.59 | 2025 | Zoryve |
| Botanix Sb INC | $14.81 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lavian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.